Zurich's AI demand splits into two distinct worlds. In banking, UBS (the world's largest wealth manager post-Credit Suisse merger), Julius Bär, Zürcher Kantonalbank, and a cluster of 200+ private banks need AI for wealth advisory automation, anti-money laundering, and regulatory reporting — but FINMA Circular 2023/1 on operational risk requires demonstrable control over technology dependencies, and sending client portfolio data to OpenAI's servers is categorically off-limits. In pharma and biotech, the Basel-Zurich corridor houses Roche, Novartis, and 1,200+ life sciences companies. Drug discovery pipelines generate terabytes of proprietary molecular data, clinical trial documentation, and patient records governed by the Human Research Act (HRA) — all requiring on-premise processing. Beyond these, Zurich's insurance cluster (Swiss Re, Zurich Insurance) deploys AI for claims processing and actuarial modeling, and the city's growing fintech scene (SIX Digital Exchange, Sygnum, SEBA) applies AI to digital asset markets. ETH Zurich and EPFL produce world-class ML talent, but competition for graduates is fierce — Google, Meta, and Apple all have Zurich AI research labs.